Weight loss jabs, such as Ozempic and Wegovy, have been celebrated for their effectiveness in combating obesity, helping individuals lose up to a fifth of their body weight. However, a concerning study has emerged, suggesting these drugs could interfere with the effectiveness of breast cancer treatments. Specifically, the research focused on women with triple negative breast cancer, an aggressive form of the disease, and found that those on glucagon-like peptide-1 receptor agonists (GLP-1s) were less likely to be cancer-free after undergoing chemotherapy and immunotherapy.
Dr. John Glees, a British consultant clinical oncologist, described the findings as 'unsettling,' highlighting the novelty of these weight loss drugs and the concern they may reduce the efficacy of cancer treatments. The study observed hundreds of women with early-stage triple negative breast cancer, with a subset continuing their GLP-1 medication alongside cancer treatment. Results showed only 28% of these women were cancer-free two years post-treatment, compared to 63% of those not on GLP-1s.
Dr. Bethania Santos, who presented the study at the San Antonio Breast Cancer Symposium, noted that GLP-1s were found within tumor and immune cells, potentially making tumor cells more resistant to standard treatments. Despite the alarming findings, experts urge patients not to panic, emphasizing the need for further research to fully understand the implications of using weight loss drugs during cancer therapy.
Triple negative breast cancer, accounting for about 15% of all breast cancers in the UK and US, is known for its rapid growth and spread, as well as fewer treatment options. The study underscores the complexity of managing cancer patients on weight loss medications and calls for careful consideration and more definitive data before making recommendations on their use during cancer treatment.
